A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021.
Yves Herman | Reuters
CureVac stock plunged 50% in extended trading Wednesday after the German biopharmaceutical company released preliminary efficacy results for its Covid-19 vaccine candidate that failed to meet success criteria.
The vaccine candidate demonstrated an interim efficacy of 47% against Covid-19 disease “of any severity,” according to a press release. The company said final analysis of the results would be completed in the coming weeks.
The late-stage clinical trial of approximately 40,000 participants across 10 countries found high prevalence of virus variants, in particular the lambda strain first detected in South America.
“While we were hoping…
